Testing Procedures For Group Sequential Clinical Trials With Multiple Survival Endpoints
Download Testing Procedures For Group Sequential Clinical Trials With Multiple Survival Endpoints PDF/ePub or read online books in Mobi eBooks. Click Download or Read Online button to get Testing Procedures For Group Sequential Clinical Trials With Multiple Survival Endpoints book now. This website allows unlimited access to, at the time of writing, more than 1.5 million titles, including hundreds of thousands of titles in various foreign languages.
Testing Procedures for Group Sequential Clinical Trials with Multiple Survival Endpoints
This research gives methods for sequential monitoring of survival data in clinical trials with multiple endpoints. We illustrate the use of marginal proportional hazards models and other survival models with various group sequential methods to test multiple survival endpoints at K interim analyses. To adjust for multiplicity at each interim analysis, we consider and extend methods developed by Tang and Geller (1999), Follmann, et al. (1994), and others. These methods are motivated, compared, and evaluated using survival data from a clinical study and using simulation studies.
Group Sequential Methods with Applications to Clinical Trials
Group sequential methods answer the needs of clinical trial monitoring committees who must assess the data available at an interim analysis. These interim results may provide grounds for terminating the study-effectively reducing costs-or may benefit the general patient population by allowing early dissemination of its findings. Group sequential methods provide a means to balance the ethical and financial advantages of stopping a study early against the risk of an incorrect conclusion. Group Sequential Methods with Applications to Clinical Trials describes group sequential stopping rules designed to reduce average study length and control Type I and II error probabilities. The authors present one-sided and two-sided tests, introduce several families of group sequential tests, and explain how to choose the most appropriate test and interim analysis schedule. Their topics include placebo-controlled randomized trials, bio-equivalence testing, crossover and longitudinal studies, and linear and generalized linear models. Research in group sequential analysis has progressed rapidly over the past 20 years. Group Sequential Methods with Applications to Clinical Trials surveys and extends current methods for planning and conducting interim analyses. It provides straightforward descriptions of group sequential hypothesis tests in a form suited for direct application to a wide variety of clinical trials. Medical statisticians engaged in any investigations planned with interim analyses will find this book a useful and important tool.
Group-Sequential Clinical Trials with Multiple Co-Objectives
This book focuses on group sequential methods for clinical trials with co-primary endpoints based on the decision-making frameworks for: (1) rejecting the null hypothesis (stopping for efficacy), (2) rejecting the alternative hypothesis (stopping for futility), and (3) rejecting the null or alternative hypothesis (stopping for either futility or efficacy), where the trial is designed to evaluate whether the intervention is superior to the control on all endpoints. For assessing futility, there are two fundamental approaches, i.e., the decision to stop for futility based on the conditional probability of rejecting the null hypothesis, and the other based on stopping boundaries using group sequential methods. In this book, the latter approach is discussed. The book also briefly deals with the group sequential methods for clinical trials designed to evaluate whether the intervention is superior to the control on at least one endpoint. In addition, the book describes sample size recalculation and the resulting effect on power and type I error rate. The book also describes group sequential strategies for three-arm clinical trials to demonstrate the non-inferiority of experimental intervention to actively control and to assess the assay sensitivity to placebo control.